Relationship between oral mucositis and high-dose methotrexate therapy in pediatric acute lymphoblastic leukemia

被引:4
|
作者
Maiguma, T. [1 ]
Hayashi, Y. [2 ]
Ueshima, S. [2 ]
Kaji, H. [1 ]
Egawa, T. [1 ]
Chayama, K. [4 ]
Morishima, T. [4 ]
Kitamura, Y. [3 ]
Sendo, T. [2 ]
Gomita, Y. [1 ]
Teshima, D. [1 ]
机构
[1] Shujitsu Univ, Dept Clin Pharm, Sch Pharm, Okayama 7038516, Japan
[2] Okayama Univ Hosp, Dept Hosp Pharm, Okayama, Japan
[3] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Clin Pharmaceut Sci, Okayama, Japan
[4] Okayama Univ Hosp, Dept Pediat, Okayama, Japan
关键词
high-dose methotrexate chemotherapy; pediatric acute lymphoblastic leukemia; oral mucositis; human epidermal keratinocytes; cell viability; pharmacokinetic parameters;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: Oral mucositis is a major toxicity in the high-dose methotrexate (HD-MTX) treatment for children with acute lymphoblastic leukemia (ALL). The first aim Of this Study was to evaluate the relationship between the MTX serum concentration and Occurrence of oral mucositis in pediatric ALL patients. The second aim was to clarify the relationship between MTX exposure and epidermal keratinocyte cell injury using an in vitro study. Methods: 49 patients were treated according to the Japan Association of Childhood Leukemia Study (JACLS) ALL-HR02 protocol. This protocol involves HD-MTX treatment (3 g/m(2) for 24-h i.v. infusion). The MTX serum concentrations were measured by a fluorescence polarization immunoassay. The relationship between oral mucositis and MTX serum concentrations 48 and 72 h after administration was determined. The cell toxicity or MTX for epidermal keratinocytes was analyzed by using a cell viability assay (WST-1 assay). In addition, pharmacokinetic evaluation for clearance, AUC extrapolated from 48 h to infinity (AUC(48h-infinity)) and elimination half-life 01,1210 were done using the 1-compartmental models. Results: Oral mucositis occurred in 24 patients (49.0%), in whom 20 patients (83.3% in oral mucositis group) showed WHO severity Grade 1 or 2. Only 4 patients (16.7% in oral mucositis group) showed Grade 3 severity. 22 patients (44.9%) had oral mucositis in the group With a concentration under 10(-6) M 48 h after MTX administration. There was no significant deference among the cell viabilities in the Concentrations of 10(-6) M, 10(-5) M and 10(-4) M 48 h after the MTX exposure. However, the cell viability obtained 24 h after the MTX exposure was significantly different from the respective cell viability 48, 72 and 96 h after the MTX exposure. In the group with oral mucositis, the clearance decreased significantly (p = 0.042), and the t(1/2 beta) (p = 0.025) and AUC(48h-infinity), (P = 0.025) increased significantly compared with the non-symptom group. Conclusions: It seems that there is no significant relationship between the serum MTX concentration and oral mucositis. This in vitro Study has demonstrated that the cell injury was related to the duration of MTX exposure rather than a high MTX concentration.
引用
收藏
页码:584 / 590
页数:7
相关论文
共 50 条
  • [21] Sequential high-dose therapy of adult acute lymphoblastic leukemia
    Mehta, J
    Singhal, S
    Treleaven, J
    Horton, C
    Powles, R
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 811 - 811
  • [22] Monitoring of methotrexate and 7-hydroxymethotrexate in saliva from children with acute lymphoblastic leukemia receiving high-dose consolidation treatment: Relation to oral mucositis
    Albertioni, F
    Rask, C
    Schroeder, H
    Peterson, C
    ANTI-CANCER DRUGS, 1997, 8 (02) : 119 - 124
  • [23] High-Dose Methotrexate-Related Toxicity in Children with Acute Lymphoblastic Leukemia
    Gustafsson, Christina Egnell
    Frederiksen, Grete Gotzsche
    Thorwaldson, Josefine
    Heyman, Mats
    Harila-Saari, Arja
    Ranta, Susanna
    BLOOD, 2022, 140 : 6033 - 6034
  • [24] High-dose methotrexate-related pneumonitis in a child with acute lymphoblastic leukemia
    Rakez, Rim
    Boufrikha, Wiem
    Cheffai, Areej
    Boukhriss, Sarra
    Laatiri, Mohamed Adnene
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, : 506 - 510
  • [25] High-dose methotrexate for the treatment of acute lymphoblastic leukemia in children (a pharmacokinetic study)
    Slany, J
    Grundmann, M
    Brozmanova, H
    Blazek, B
    Sterba, J
    DRUG RESISTANCE IN LEUKEMIA AND LYMPHOMA II, 1997, 3 : 183 - 188
  • [26] TREATMENT OF ACUTE LYMPHOBLASTIC-LEUKEMIA IN ADULTS WITH HIGH-DOSE PREDNISOLONE AND METHOTREXATE
    KORNINGER, C
    BETTELHEIM, P
    HINTERBERGER, W
    NIESSNER, H
    NEUMANN, E
    LECHNER, K
    BLUT, 1983, 47 (03): : 170 - 170
  • [27] Hemostatic side effects of high-dose methotrexate in childhood acute lymphoblastic leukemia
    Fisgin, T
    Yarali, N
    Kara, A
    Bozkurt, C
    Birgen, D
    Erten, U
    Duru, F
    PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2004, 21 (01) : 77 - 83
  • [28] Effects of high-dose methotrexate on the hemostatic system in childhood acute lymphoblastic leukemia
    Totan, M
    Dagdemir, A
    Ak, AR
    Albayrak, D
    Kucukoduk, S
    MEDICAL AND PEDIATRIC ONCOLOGY, 2001, 36 (04): : 429 - 433
  • [29] Prevalence of leukoencephalopathy in children treated for acute lymphoblastic leukemia with high-dose methotrexate
    Reddick, WE
    Glass, JO
    Helton, KJ
    Langston, JW
    Xiong, XP
    Wu, SJ
    Pui, CH
    AMERICAN JOURNAL OF NEURORADIOLOGY, 2005, 26 (05) : 1263 - 1269
  • [30] SIDE EFFECTS OF HIGH-DOSE METHOTREXATE TREATMENT TO CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA
    Zhou, M.
    Jiang, Y.
    PEDIATRIC BLOOD & CANCER, 2013, 60 : 213 - 213